AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04062695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 MG Oral Tablet [Xeljanz]
Description: verum tablets
Study NCT04062695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: tablets containing placebo
Study NCT03983954 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
Description: Obinutuzumab is given intravenous (I.V.) 1,000 mg concentrate for solution for infusion.~NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
Study NCT03983954 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
Description: NAP is given as an intravenous (I.V.) bolus injection at multiple doses. Durvalumab is given at a dose of 1120 mg, I.V, 1- 1.5 hours after completion of the administration of NAP on the second day of each 21-day cycle, and when administered as monotherapy at a dose of 1500 mg delivered once every 28 days.
Study NCT02970383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial prescription for 10 narcotic tabs
Description: Reduced number of pills in initial prescription post-operatively
Study NCT02970383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inital prescription for 30 narcotic tabs
Study NCT02801331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Vibrotactile Stimulation (SVS)
Description: Infant crib mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle, stochastic vibration during mattress stimulations.
Study NCT03837717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holding
Description: Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
Study NCT03837717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
Study NCT03837717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Holding
Description: Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
Study NCT01368419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
Study NCT01368419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6～15MV X-ray, 2Gy/time，5times/week，6 weeks
Study NCT01257347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure of adherence report to clinician
Description: During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (\<10 minutes) in the interpretation and use of the report at the time of enrollment.
Study NCT01257347 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MedSignals pillbox
Description: (Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
Study NCT01257347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedSignals pillbox
Description: (Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
Study NCT02642705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training N
Description: Exercise training and ambient air breathing
Study NCT02642705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training H
Description: Exercise training and hypoxic breathing
Study NCT02642705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant load exercise training N
Description: Exercise training and ambient air breathing
Study NCT02642705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant load exercise training H
Description: Exercise training and hypoxic breathing
Study NCT02642705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic conditioning at rest
Description: Hypoxic breathing at rest
Study NCT02642705 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxic conditioning at rest
Description: Normoxic breathing at rest (placebo)
Study NCT04108078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Policy Plus (HP+)
Description: HP+ is a stigma-reduction intervention that is designed to reduce stigmatizing attitudes and beliefs among all workers (clinical and non- clinical) in a healthcare facility.
Study NCT04108078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Many Men Many Voices (3MV)
Description: 3MV is a group-level HIV prevention intervention designed specifically for use with Black men who have sex with men (MSM). It is a 7- session intervention that is facilitated by trained peers. The intervention has previously been adapted and used with MSM in Ghana.
Study NCT04108078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Education, Empathy and Empowerment (HIVE3)
Description: The HIVE3 is a telephone-based peer support intervention. It utilizes trained peers, who are also MSM, to provide emotional, informational and affirming support via text message or phone. The intervention was developed specifically for use with MSM in Ghana and demonstrated acceptability and feasibility in a preliminary study in Ghana.
Study NCT03122171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Treatment
Description: Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
Study NCT04381065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal KinetiGraph® (PKG®) System
Description: The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch~* Data-driven report known as the PKG®~The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® also provides an assessment of daytime somnolence and an indication of propensity for impulsive behaviors.
Study NCT04381065 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Personal KinetiGraph® (PKG®) Watch
Description: The Personal KinetiGraph (PKG®) System consists of the following:~* A wrist-worn movement recording device known as the PKG® Watch, designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period~* Proprietary algorithms to translate raw movement data collected by the PKG® Watch
Study NCT00053625 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep brain stimulation
Description: Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
Study NCT02102555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Single dose of one gram of IV acetaminophen given in pre-operative area
Study NCT02102555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (IV normal saline)
Study NCT01232283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
Study NCT01232283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
Study NCT01232283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
Study NCT01232283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
Study NCT01232283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical or Phototherapy Therapy
Description: Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
Study NCT01232283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical or Phototherapy Therapy
Description: Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (\< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
Study NCT02986464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Prototype
Description: VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
Study NCT02986464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pharmacological Treatment
Description: According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and the pain clinic nurse.
Study NCT00671788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given orally
Study NCT00671788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02668640 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection
Study NCT03912389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, IV infusion
Study NCT03912389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT03912389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT03912389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (or carboplatin)
Description: IV infusion
Study NCT03912389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (or carboplatin)
Description: IV infusion
Study NCT03912389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT01811238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone
Description: Targin 5mg, 10mg, 20mg up to 40mg b.i.d
Study NCT04411615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: rTG form Omega-3
Study NCT00828711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 100
Description: Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study NCT00828711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 150
Description: Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study NCT00828711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVI 200
Description: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
Study NCT03035448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete.
Study NCT03035448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Presentation
Description: Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
Study NCT06405919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology
Description: Thyroidectomy for patients and histological examination of specimen to determine incidence of malignancy.
Study NCT01033838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectosigmoid resection
Study NCT01033838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rectosigmoid resection
Study NCT01164761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
Study NCT01164761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace
Description: Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
Study NCT02757157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water-based walking
Description: Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.
Study NCT02757157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Land-based walking
Description: Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured.
Study NCT03710512 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral sagittal split osteotomy
Description: Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
Study NCT01198912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: during 56 days
Study NCT01198912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline 100 mg
Description: during 56 days
Study NCT02110979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of a PDA to assist shared decision making
Study NCT02460289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment: Minoxidil 5% / Botanical Hair Solution for Men
Study NCT04722406 — intervention group
Intervention type: OTHER
Intervention: This item is not applicable to our observational study.
Description: This item is not applicable to our observational study.
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 3C1A2B4D
Description: Participants receive test meals in the sequence 3C1A2B4D
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 2A3D4C1B
Description: Participants receive test meals in the sequence 2A3D4C1B
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 2D4B3A1C
Description: Participants receive test meals in the sequence 2D4B3A1C
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 3B2C1D4A
Description: Participants receive test meals in the sequence 3B2C1D4A
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 4C2B1A3D
Description: Participants receive test meals in the sequence 4C2B1A3D
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence:1B4D3C2A
Description: Participants receive test meals in the sequence 1B4D3C2A
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence:4A1C2D3B
Description: Participants receive test meals in the sequence 4A1C2D3B
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence:1D3A4B2C
Description: Participants receive test meals in the sequence 1D3A4B2C
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 4D3B2C1A
Description: Participants receive test meals in the sequence 4D3B2C1A
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 3A4C1B2D
Description: Participants receive test meals in the sequence 3A4C1B2D
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 1C2A3D4B
Description: Participants receive test meals in the sequence 1C2A3D4B
Study NCT03305718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal sequence: 2B1D4A3C
Description: Participants receive test meals in the sequence 2B1D4A3C
Study NCT01542762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Study NCT01298830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 CellBeads
Description: GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
Study NCT00800046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventriculoplasty System
Description: Mitral valve repair due to functional disease
Study NCT03638323 — intervention group
Intervention type: OTHER
Intervention: Speech therapy
Description: During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
Study NCT05034549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: The non-invasive ventilator at home (≥5h/ night)
Study NCT04509271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MicRNAs battery kits
Description: Novel peripheral blood diagnostic biomarker for MCI due to AD.